NanJing Pharmaceutical Co Ltd
Nanjing Pharmaceutical Group Company Limited engages in the drug distribution businesses in China. It also involved in the wholesale and retail of medical device distribution; pharmaceutical logistics; and internet drug retail business. The company was formerly known as NanJing Pharmaceutical Company Limited and change its name to Nanjing Pharmaceutical Group Company Limited in December 2025. Nan… Read more
NanJing Pharmaceutical Co Ltd (600713) - Total Liabilities
Latest total liabilities as of September 2025: CN¥26.09 Billion CNY
Based on the latest financial reports, NanJing Pharmaceutical Co Ltd (600713) has total liabilities worth CN¥26.09 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NanJing Pharmaceutical Co Ltd - Total Liabilities Trend (1994–2024)
This chart illustrates how NanJing Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
NanJing Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of NanJing Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TechnoPro Holdings Inc
PINK:TCCPY
|
USA | $60.19 Billion |
|
Bannerman Energy Ltd
AU:BMN
|
Australia | AU$8.66 Million |
|
Guardian Capital Group Limited
PINK:GRCGF
|
USA | $748.64 Million |
|
Suzhou Huaya Intelligence Technology Co Ltd
SHE:003043
|
China | CN¥911.84 Million |
|
RLH Properties S.A.B. de C.V
MX:RLHA
|
Mexico | MX$23.47 Billion |
|
Formosa Taffeta Co Ltd
TW:1434
|
Taiwan | NT$16.13 Billion |
|
Bandwidth Inc
NASDAQ:BAND
|
USA | $640.59 Million |
|
Sapphire Foods India Limited
NSE:SAPPHIRE
|
India | ₹18.16 Billion |
Liability Composition Analysis (1994–2024)
This chart breaks down NanJing Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.77 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NanJing Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NanJing Pharmaceutical Co Ltd (1994–2024)
The table below shows the annual total liabilities of NanJing Pharmaceutical Co Ltd from 1994 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥22.89 Billion | +8.18% |
| 2023-12-31 | CN¥21.16 Billion | -15.23% |
| 2022-12-31 | CN¥24.96 Billion | +20.84% |
| 2021-12-31 | CN¥20.65 Billion | +11.10% |
| 2020-12-31 | CN¥18.59 Billion | +6.56% |
| 2019-12-31 | CN¥17.45 Billion | +12.95% |
| 2018-12-31 | CN¥15.45 Billion | +21.25% |
| 2017-12-31 | CN¥12.74 Billion | +16.95% |
| 2016-12-31 | CN¥10.89 Billion | +9.93% |
| 2015-12-31 | CN¥9.91 Billion | +11.02% |
| 2014-12-31 | CN¥8.92 Billion | +6.74% |
| 2013-12-31 | CN¥8.36 Billion | +5.66% |
| 2012-12-31 | CN¥7.91 Billion | +3.22% |
| 2011-12-31 | CN¥7.67 Billion | +7.83% |
| 2010-12-31 | CN¥7.11 Billion | +23.16% |
| 2009-12-31 | CN¥5.77 Billion | +30.22% |
| 2008-12-31 | CN¥4.43 Billion | +3.14% |
| 2007-12-31 | CN¥4.30 Billion | +41.24% |
| 2006-12-31 | CN¥3.04 Billion | +13.48% |
| 2005-12-31 | CN¥2.68 Billion | +6.42% |
| 2004-12-31 | CN¥2.52 Billion | +24.87% |
| 2003-12-31 | CN¥2.02 Billion | +53.94% |
| 2002-12-31 | CN¥1.31 Billion | +87.84% |
| 2001-12-31 | CN¥697.93 Million | -5.98% |
| 2000-12-31 | CN¥742.31 Million | +48.00% |
| 1999-12-31 | CN¥501.56 Million | +13.91% |
| 1998-12-31 | CN¥440.31 Million | +109.87% |
| 1997-12-31 | CN¥209.80 Million | -5.61% |
| 1996-12-31 | CN¥222.28 Million | +16.92% |
| 1995-12-31 | CN¥190.11 Million | +7.72% |
| 1994-12-31 | CN¥176.47 Million | -- |